Antibodies in oncology are being equipped with toxic cargoes and effector functions that can
kill cells at very low concentrations. A key challenge is that most targets on cancer cells are …

The ability to leverage antibodies to agonize disease relevant biological pathways has
tremendous potential for clinical investigation. Yet while antibodies have been successful as …

Purpose: Activating T cell costimulatory receptors is a promising approach for cancer
immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with …

The amplification of weak transient protein–protein interactions to elicit robust immune
responses is a recurring theme in immune processes (1)(Fig. 1). Given the often highly …

Antibodies are fundamental effectors of humoral immunity, and have become a highly
successful class of therapeutics. There is increasing evidence that antibodies utilize …

The amplification ofweak transient protein-protein interactions to elicit robust immune
responses is a recurring theme in immune processes (1)(Fig. 1). Given the often highly …